AMLX vs SLS: Which Stock Is the Better Buy?
Amylyx Pharmaceuticals, Inc. and SELLAS Life Sciences Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AMLX vs SLS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Amylyx Pharmaceuticals, Inc. (AMLX) | SELLAS Life Sciences Group, Inc. (SLS) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-144.74M | $-26.86M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -47.4% | -37.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full AMLX vs SLS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AMLX's full financials → Open SLS's full financials →More comparisons
Frequently asked questions
Which is bigger, AMLX or SLS?
SELLAS Life Sciences Group, Inc. is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, AMLX or SLS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.